REGN / Regeneron Pharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 (August 1, 2025) R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 (August 1, 2025) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

ncorporation, as amended.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF REGENERON PHARMACEUTICALS, INC. Under Section 805 of the Business Corporation Law The undersigned, being the Executive Vice President, General Counsel and Secretary of Regeneron Pharmaceuticals, Inc. (the “Corporation”), hereby certifies that: 1.The name of the Corporation is Regeneron Pharmaceuticals, Inc. 2.The Certifica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON

Amendment No. 2 to Amended and Restated License and Collaboration Agreement, dated July 27, 2015 and entered into effective as of July 1, 2015, by and between

Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT This AMENDMENT NO. 2 (this "Second Amendment") to that certain AMENDED AND R

Press Release, dated August 1, 2025, Reporting Second Quarter 2025 Financial and Operating Results.

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2025 Financial and Operating Results •Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024 •Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion •EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion •GAAP E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 (June 13, 2025) REG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 (June 13, 2025) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034

Letter to Shareholders Notice of Annual Meeting of Shareholders Introduction Board of Directors Corporate Governance The Company Compensation-Related Matters Other Matters Appendix A Appendix B Appendix C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON

Q1 2025

Exhibit 99.1 Press Release Regeneron Reports First Quarter 2025 Financial and Operating Results •First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22 •First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024 •First quarter 2025 EYLEA HD® U.S. net sales increased 54% to $307 mil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 (April 29, 2025) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

Letter to Shareholders Notice of Annual Meeting of Shareholders Introduction Board of Directors Corporate Governance The Company Compensation-Related Matters Other Matters Appendix A Appendix B Appendix C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com April 3, 2025

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com April 3, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Bonnie Baynes and Angela Connell Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended Decembe

nsider Trading Policy.

Exhibit 19.1 POLICY NAME: 230 Securities Investments Effective Date: 01/14/01 Revised Date: 01/24/25 Contact: ***@REGENERON.COM PURPOSE Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") and its directors, officers, and employees and certain other related persons are subject to "insider trading" laws. These laws prohibit individuals with material non-public information about a company

Restated Amendment Agreement, dated December 30, 2014 and entered into effective as of May 7, 2012, by and between Bayer HealthCare LLC and the Registrant.

Exhibit 10.8.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. RESTATED AMENDMENT AGREEMENT This Amendment Agreement (this “Amendment Agreement”) dated as of May 7, 2012, is by and between Regeneron Pharmaceutica

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. Except as otherwise noted, each of the entities listed below is directly or indirectly wholly owned by Regeneron Pharmaceuticals, Inc. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Checkmate Pharmaceuticals, Inc. Delaware Decibel Therapeutics, Inc. Delaware Eastside Campus Holdings LLC New York Loop Road

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON PHAR

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, par value $0.001 per share (the “Common Stock”), of Regeneron Pharmaceuticals, Inc. (the “Company”) which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 (February 4, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 (February 4, 2025) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

Q4 2024

Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion •Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023 •Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues i

J.P. Morgan Healthcare Conference JANUARY 13, 2025 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially.

Exhibit 99.2 J.P. Morgan Healthcare Conference JANUARY 13, 2025 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially. 2 Strategy & Business Update J.P. Morgan Healthcare Conference 2025 Leonard S. Schleifer, MD, PhD Co - Founder, Board Co - Chair, President & Chief Executive Officer 3 Note regarding forward -

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 (January 13, 2025) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43

Exhibit 99.1 Press Release Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category le

Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association, as trustee under the Indenture.

Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

As filed with the Securities and Exchange Commission on October 31, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 31, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 (October 31, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 (October 31, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

Q3 2024

Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2024 Financial and Operating Results •Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 •Third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023 •Third quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter

Filing Fee Table.

Calculation of Filing Fee Tables S-3 REGENERON PHARMACEUTICALS, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Eff

Specimen Common Stock Certificate.

EXHIBIT 4.4 COMMON STOCK COMMON STOCK [ ] NUMBER REGENERON [ ] SHARES INCORPORATED UNDER THE LAWS OF THE STATE OF NEW YORK SEE REVERSE FOR CERTAIN DEFINITIONS Regeneron Pharmaceuticals, Inc. CUSIP 75886F 10 7 This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $.001 PER SHARE, OF Regeneron Pharmaceuticals, Inc., transferable on the books of the Corpo

(Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended

Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 3 to the Master Agreement This Amendment No. 3 (“Amendment No. 3”) to the Master Agreement is entered into and effective as of August 1, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGEN

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 (October 7, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19

Q2 2024

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2024 Financial and Operating Results •Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023 •Second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023 •Second quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® increased 2% to $1.53 billi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 (August 1, 2024) R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 (August 1, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com August 1, 2024

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com August 1, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Frank Wyman and Angela Connell Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 (July 8, 2024) REGEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 (July 8, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034 13

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 (June 14, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com May 20, 2024

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com May 20, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Franklin Wyman and Angela Connell Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended Decembe

and Alnylam Pharmaceuticals, Inc.

Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 2 to the Master Agreement This Amendment No. 2 (“Amendment No. 2”) to the Master Agreement is entered into and effective as of March 7, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 (May 2, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorpor

Q1 2024

Exhibit 99.1 Press Release Regeneron Reports First Quarter 2024 Financial and Operating Results •First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7% •First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023 •First quarter 2024 U.S. net sales for EYL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Company Letter to Shareholders Table of Contents Users’ Guide Board of Directors The Company Shareholders Compensation-Related Matters General Information about the Meeting and Other Matters Appendix A Appendix B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

REGN / Regeneron Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Regeneron Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 75886F107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule i

REGN / Regeneron Pharmaceuticals, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (revised 2023). (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2023, filed February 5, 2024.)

Exhibit 10.3.7 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Award and Restricted Stock 777 Old Saw Mill River Road Agreement Tarrytown, New York 10591 [NAME] RSA Number: [ ] [ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted an award of [ ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) common stock. These shares are restricted until the vest da

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan

Exhibit 10.3.6 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement for Time-Based Vesting Tarrytown, New York 10591 Option Awards [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted a Non-Qualified Option to buy [ ] shares of Regeneron Pharmaceuticals, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON PHAR

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. Name of Subsidiary* State or Other Jurisdiction of Incorporation or Organization Checkmate Pharmaceuticals, Inc. Delaware Decibel Securities Corporation Massachusetts Decibel Therapeutics Australia Pty Ltd Australia Decibel Therapeutics, Inc. Delaware Eastside Campus Holdings LLC New York Loop Road Holdings LLC New York Old Saw Mill Hold

awback Policy.

Exhibit 97.1 REGENERON PHARMACEUTICALS, INC. CLAWBACK POLICY The Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (the “Company”) believes it is appropriate for the Company to adopt this Clawback Policy (this “Policy”) to be applied to the Executive Officers (as defined below) of the Company and adopts this Policy to be effective as of the Effective Date (as defined below). 1.De

Programs (continued)

Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results •Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenues increased 14% •Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022; excluding Ronapreve(a), revenues increased 12% •Fourth quarter 2023 Du

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 (February 2, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 (February 2, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 (January 26, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-

REGN / Regeneron Pharmaceuticals, Inc. / JPMORGAN CHASE & CO - FILING REGENERON PHARMACEUTICALS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* REGENERON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock - par value $.001 per share (Title of Class of Securities) 75886F107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat

REGN / Regeneron Pharmaceuticals, Inc. / JPMORGAN CHASE & CO - FILING REGENERON PHARMACEUTICALS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* REGENERON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock - par value $.001 per share (Title of Class of Securities) 75886F107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat

J.P.Morgan Healthcare Conference JANUARY 8, 2024 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially.

Exhibit 99.1 J.P.Morgan Healthcare Conference JANUARY 8, 2024 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially. 2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer 3 Note regarding forward - looking statements This presenta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 (January 8, 2024)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 (January 8, 2024) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 (November 2, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

$4.370–$4.455 billion

Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2023 Financial and Operating Results •Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022 •Third quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $3.10 billion versus third quarter 2022 •Third quarter 2023 U.S. net sales for EYLEA® and EYLEA HD were $1.49 billion, including $43

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGEN

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 (October 5, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19

DBTX / Decibel Therapeutics Inc / Regeneron Pharmaceuticals Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Decibel Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24343R106 (CUSIP Number) Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Regeneron Pharmaceuticals, Inc. 777 Old Sa

Press Release dated September 25, 2023, issued by Regeneron Pharmaceuticals, Inc.

Exhibit (a)(5)(A) Press Release Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss TARRYTOWN, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) DECIBEL THERAPEUTICS, INC. (Name of Subject C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) DECIBEL THERAPEUTICS, INC. (Name of Subject Company) SYMPHONY ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DECIBEL THERAPEUTICS, INC. (Name of Subject C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DECIBEL THERAPEUTICS, INC. (Name of Subject Company) SYMPHONY ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 (June 9, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-1

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 (September 1, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DECIBEL THERAPEUTICS, INC. (Name of Subject C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DECIBEL THERAPEUTICS, INC. (Name of Subject Company) SYMPHONY ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value

Letter of Transmittal.

 Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of DECIBEL THERAPEUTICS, INC.

Confidentiality Agreement, dated as of June 30, 2023, between Decibel Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc.

Exhibit (d)(7) EXECUTION VERSION CONFIDENTIAL Decibel Therapeutics, Inc. 1325 Boylston Street, Suite 500 Boston, MA 02215 June 30, 2023 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Confidentiality Agreement In connection with your consideration of a possible negotiated business combination transaction involving Decibel Therapeutics, Inc. (together with its s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DECIBEL THERAPEUTICS, INC. (Name of Subject Company) SYMPHONY A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DECIBEL THERAPEUTICS, INC. (Name of Subject Company) SYMPHONY ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share

Exclusivity Agreement, dated as of June 30, 2023, by and between Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc.

Exhibit (d)(8) EXECUTION STRICTLY CONFIDENTIAL June 30, 2023 Decibel Therapeutics, Inc.

Offer to Purchase, dated August 25, 2023.

TABLE OF CONTENTS  Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Decibel Therapeutics, Inc.

Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

 Exhibit (a)(1)(D) Offer To Purchase All Outstanding Shares of Common Stock of DECIBEL THERAPEUTICS, INC.

Summary Advertisement as published in The New York Times on August 25, 2023

Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

 Exhibit (a)(1)(C) Offer To Purchase All Outstanding Shares of Common Stock of DECIBEL THERAPEUTICS, INC.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) DECIBEL THERAPEUTICS, INC.

Joint Filing Agreement, dated as of August 18, 2023, by and between Regeneron Pharmaceuticals, Inc. and Symphony Acquisition Sub, Inc.

Exhibit 99.4 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accurac

Series B Preferred Stock Agreement, dated as of November 15, 2017, by and between Decibel Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (incorporated by reference to Exhibit 99.3 to the Schedule 13D filed by Regeneron Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on August 18, 2023).

Exhibit 99.3 Execution Version DECIBEL THERAPEUTICS, INC. SERIES B PREFERRED STOCK PURCHASE AGREEMENT November 15, 2017 TABLE OF CONTENTS Page 1. Purchase and Sale of Preferred Stock 1 1.1 Sale and Issuance of Series B Preferred Stock 1 1.2 Closing; Delivery 1 1.3 Use of Proceeds 1 1.4 Defined Terms Used in this Agreement 1 2. Representations and Warranties of the Company 3 2.1 Organization, Good

DBTX / Decibel Therapeutics Inc / Regeneron Pharmaceuticals Inc - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Decibel Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 24343R106 (CUSIP Number) Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road

Joint Press Release issued by Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. on August 9, 2023 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by Regeneron Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on August 9, 2023).

Exhibit 99.1 Press Release Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Decibel Therapeutics, Inc. (Name of Subject Company) S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Decibel Therapeutics, Inc. (Name of Subject Company) Symphony Acquisition Sub, Inc. (Offeror) Regeneron Pharmaceuticals, Inc. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001 PAR VALUE P

Social Media Posts from August 9, 2023 (incorporated by reference to Exhibit 99.2 to the Schedule TO-C filed by Regeneron Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on August 9, 2023).

Exhibit 99.2 Twitter Post LinkedIn Post Instagram Stories Post -2- Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron”) and Decibel Therapeutics, Inc. (“Decibel”), including regarding Regeneron’s proposed acquisition of Decibel, the

### Contact Information: Ryan Crowe Christina Chan Investor Relations Corporate Affairs 914-847-8790 914-847-8827 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2023 Financial and Operating Results •Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022 •Second quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022 •Second quarter 2023 EYLEA® U.S. net sales were $1.50 billion •Second quarter 2023 GAAP

Waiver and Consent, dated as of April 14, 2023, pursuant to the Amended and Restated Employment Agreement, dated as of November 14, 2008, between the Registrant and Leonard S. Schleifer, M.D., Ph.D.

Exhibit 10.3 CONFIDENTIAL April 14, 2023 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 Attention: Arthur F. Ryan, Chair of the Corporate Governance and Compliance Committee, Member of the Board of Directors and Presiding Director Christine A. Poon, Chair of the Compensation Committee of the Board of Directors Joseph J. LaRosa, Executive Vice President,

Amendment No. 1 to Master Agreement, dated as of April 10, 2023, by and between the Registrant and Alnylam Pharmaceuticals, Inc. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2023, filed August 3, 2023.)

Exhibit 10.2 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 1 to the Master Agreement This Amendment No. 1 (“Amendment No. 1”) to the Master Agreement is entered into and effective as of April 10, 20

First Amendment to Amended and Restated License and Collaboration Agreement by and between the Registrant and Aventis Pharmaceuticals Inc., dated May 1, 2013. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2023, filed August 3, 2023.)

Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT This First Amendment to the Amended and Restated License and Collaboration

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 (August 3, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 (June 9, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034 1

Amendment to the Amended and Restated By-Laws effective June 9, 2023. (Incorporated by reference from the Form 8-K for the Registrant filed June 14, 2023.)

Exhibit 3.2 AMENDMENT TO THE BY-LAWS OF REGENERON PHARMACEUTICALS, INC. This Amendment (this “Amendment”) to the Amended and Restated By-Laws of Regeneron Pharmaceuticals, Inc., as amended through December 16, 2016 and currently in effect (the “By-Laws”), hereby amends the By-Laws as follows: 1. Section 7 of Article II of the By-Laws is hereby amended and restated in its entirety as follows: Secti

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Regeneron Pharmaceuticals, Inc. Name of persons relying on exemption: Boston Common Asset Managemen

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Regeneron Pharmaceuticals, Inc. Name of persons relying on exemption: Boston Common Asset Management Address of persons relying on exemption: 200 State Street, 7th Floor Boston, MA 02109 Written materials are submitted pursuant to Rule 14a-6(g) (1)

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 (May 4, 2023) REGENER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 (May 4, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorpor

First Amendment to Cash Incentive Bonus Plan. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended March 31, 2023, filed May 4, 2023.)

Exhibit 10.1 FIRST AMENDMENT TO THE REGENERON PHARMACEUTICALS, INC. CASH INCENTIVE BONUS PLAN THIS AMENDMENT (this “Amendment”) is made as of March 22, 2023 by Regeneron Pharmaceuticals, Inc., a New York corporation (the “Company”). WHEREAS, the Company has heretofore established and maintains the Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan (the “Plan”); WHEREAS, pursuant to Section

$4.200–$4.435 billion

Exhibit 99.1 Press Release Regeneron Reports First Quarter 2023 Financial and Operating Results •First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022 •First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022 •First quarter 2023 EYLEA® U.S. net sales were $1.43 billion •First quarter 2023 GAAP diluted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

COMPANY LETTER TO SHAREHOLDERS USERS’ GUIDE PROXY DASHBOARD PROXY HIGHLIGHTS BOARD OF DIRECTORS MEET THE BOARD BOARD COMMITTEES BOARD GOVERNANCE COMPENSATION OF DIRECTORS PROPOSAL 1 ELECTION OF DIRECTORS THE COMPANY EXECUTIVE OFFICERS OF THE COMPANY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

COURTESY PDF OF PROXY STATEMENT

2023 PROXY STATEMENT AND NOTICE OF ANNUAL SHAREHOLDER MEETINGPLEASE VIEW OUR 2022 RESPONSIBILITY REPORT investor.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 (April 14, 2023) R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 (April 14, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-1903

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 10, 2023) R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 10, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-1903

Third Amended and Restated Participation Agreement, dated as of March 27, 2023, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time. (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)

Exhibit 10.1 Execution Version Third Amended and Restated Participation Agreement dated as of March 27, 2023 and effective as of the Restatement Date among Old Saw Mill Holdings LLC, as Lessee, BA Leasing BSC, LLC, as Lessor, Bank of America, N.A., not in its individual capacity, except as expressly stated herein, but solely as Administrative Agent, The Persons Named on Schedule II Hereto, as Rent

Third Amended and Restated Lease and Remedies Agreement, dated as of March 27, 2023, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor. (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)

Exhibit 10.2 Execution Version Prepared by and Upon Recording Return to: Chapman and Cutler LLP 320 S. Canal Street, 27 Floor Chicago, IL 60603 Attn: Phillip Edison Third Amended and Restated Lease and Remedies Agreement Dated as of March 27, 2023 and effective as of the Restatement Date between Old Saw Mill Holdings LLC, as Lessee and BA Leasing BSC, LLC, as Lessor Regeneron 2022 Lease Financing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 (March 27, 2023) R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 (March 27, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-1903

Third Amended and Restated Guaranty, dated as of March 27, 2023, made by the Registrant, Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors. (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)

Exhibit 10.3 Execution Version Third Amended and Restated Guaranty dated as of March 27, 2023 and effective as of the Restatement Date made by Regeneron Pharmaceuticals, Inc., as Parent Guarantor, and the Subsidiary Guarantors party hereto from time to time Table of Contents Section Heading Page Section 1. Guarantee 2 Section 2. Guarantor’s Obligations Unconditional 4 Section 3. Subordination of S

REGN / Regeneron Pharmaceuticals Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp

REGN / Regeneron Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01773-regeneronpharmaceuti.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Regeneron Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 75886F107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19034 REGENERON PHAR

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. Name of Subsidiary* State or Other Jurisdiction of Incorporation or Organization Checkmate Pharmaceuticals, Inc. Delaware Eastside Campus Holdings LLC New York Loop Road Holdings LLC New York Old Saw Mill Holdings LLC New York OSMR Holdings Bermuda Regeneron Assurance, Inc. New York Regeneron Atlantic Holdings Bermuda Regeneron Belgium B

$4.200–$4.435 billion

Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results •Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14% •Full year 2022 revenues decreased 24% to $12.17 billion versus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues inc

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 (February 3, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

REGN / Regeneron Pharmaceuticals Inc / JPMORGAN CHASE & CO - FILING REGENERON PHARMACEUTICALS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* REGENERON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock - par value $.001 per share (Title of Class of Securities) 75886F107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate

J.P. Morgan Healthcare Conference January 9, 2023 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially.

Exhibit 99.1 J.P. Morgan Healthcare Conference January 9, 2023 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially. J.P. Morgan Healthcare Conference 2023 Strategy & Business Update 2 Leonard S. Schleifer, MD, PhD Co - Founder, President & Chief Executive Officer 3 Note regarding forward - looking statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 (January 9, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 (January 9, 2023) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19

Credit Agreement, dated as of December 19, 2022, by and among the Registrant, as a borrower and guarantor, certain direct subsidiaries of the Registrant, as the initial subsidiary borrowers, the lenders and issuing banks party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. (Incorporated by reference from the Form 8-K for the Registrant, filed December 20, 2022.)

Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of December 19, 2022 among REGENERON PHARMACEUTICALS, INC. REGENERON HEALTHCARE SOLUTIONS, INC. REGENERON GENETICS CENTER LLC The Other Subsidiary Borrowers Party Hereto The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent BANK OF AMERICA, N.A. and U.S. BANK NATIONAL ASSOCIATION as Co-Syndication Agents CITIBANK, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 (December 19, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 (December 19, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 00

$3.515–$3.600 billion (previously $3.485–$3.655 billion)

Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2022 Financial and Operating Results ?Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV?(a)(b), revenues increased 11% ?Third quarter 2022 EYLEA? U.S. net sales increased 11% versus third quarter 2021 to a record $1.63 billion ?Third quarter 2022 Dupixent? global net sales(c)(recorded

Modification No. 02 to Base Agreement, dated as of August 2, 2022, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and Advanced Technology International.

Exhibit 10.1 August 2, 2022 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 Attention: Subject: Modification No. 02 Reference: MCDC Base Agreement No. 2020-504 Dear : In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 02 hereby amends the Base Agreement as follows: DESCRIPTION OF MODIFICATION 1) References in the MCDC

Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.7 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Firm Fixed Price Page 1 Of 4 2. Amendment/Modification No. P00003 3. Effective Date 2021JUL08 4. Requisition/Purchase Req No. SEE SCHEDULE 5. Project No. (If applicable) 6. Issued By Code W15QKN 7. Administered By (If other than Item 6) Code W58P05 ARMY CONTRACTING COMMAND - NJ PICATINNY ARSENAL, NJ 07806-5000 EMAI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENER

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 (November 3, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.6 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Firm Fixed Price Page 1 Of 9 2. Amendment/Modification No. P00002 3. Effective Date 2021-JUN-17 4. Requisition/Purchase Req

Modification No. 03 to Project Agreement, dated as of May 21, 2021, by and between the Registrant and Advanced Technology International.

Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. May 20, 2021 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY 10591 Attention: Subject: Modification No. 03 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Base

Modification No. 04 to Project Agreement, dated as of July 12, 2021, by and between the Registrant and Advanced Technology International.

Exhibit 10.3 June 23, 2021 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 Attention: Subject: Modification No. 04 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Base Agreement No. 2020-504 Dear : This purpose of this modification is to memorialize the Department of Health and Human Services' rescission of the Health Resources Priority and Allocations Sys

Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.5 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Firm Fixed Price Page 1 Of 7 2. Amendment/Modification No. P00001 3. Effective Date 2021MAR09 4. Requisition/Purchase Req N

Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.8 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Firm Fixed Price Page 1 Of 2 2. Amendment/Modification No. P00007 3. Effective Date 29 JUL 2022 4. Requisition/Purchase Req

Modification No. 06 to Project Agreement, dated as of July 12, 2022, by and between the Registrant and Advanced Technology International.

Exhibit 10.4 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. June 30, 2022 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY 10591 Attention: Subject: Modification No. 06 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Base

October 7, 2022

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com October 7, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Regeneron Pharmaceuticals, Inc. Definitive Proxy Statement on Schedule 14A Filed April 21, 2022 File No. 000-190

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034 13-3444607 (Co

Regeneron Pharmaceuticals, Inc. (the "Registrant")

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. March 22, 2022 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY 10591 Attention: Subject: Modification No. 05 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Bas

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 (August 3, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON PH

### Contact Information: Ryan Crowe Christina Chan Investor Relations Corporate Communications 914-847-8790 914-847-8827 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2022 Financial and Operating Results ?Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV?(a)(b), revenues increased 20% ?Second quarter 2022 EYLEA? U.S. net sales increased 14% versus second quarter 2021 to a record $1.62 billion ?Second quarter 2022 Dupixent? global net sales(c)(re

Amended and Restated Immuno-oncology License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant and Sanofi Biotechnology SAS. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2022, filed August 3, 2022.)

Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDED AND RESTATED IMMUNO-ONCOLOGY LICENSE AND COLLABORATION AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS (on behalf of itself and its Affiliates) and REGENERON PHARMACEUTICALS, INC. Date

Fifth Amendment to Amended and Restated License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2022, filed August 3, 2022.)

Exhibit 10.3 EXECUTION VERSION CONFIDENTIAL CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. FIFTH AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT THIS FIFTH AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 (June 10, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 (June 1, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) CHECKMATE PHARMACEUTICALS, INC. (Name of Subj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) CHECKMATE PHARMACEUTICALS, INC. (Name of Subject Company) SCANDINAVIAN ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock,

Press Release dated May 31, 2022.

Exhibit (a)(5)(A) Press Release Regeneron Completes Acquisition of Checkmate Pharmaceuticals Acquisition strengthens Regeneron?s innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment Tarrytown, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CHECKMATE PHARMACEUTICALS, INC. (Name of Subj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CHECKMATE PHARMACEUTICALS, INC. (Name of Subject Company) SCANDINAVIAN ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) CHECKMATE PHARMACEUTICALS, INC. (Name of Subj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) CHECKMATE PHARMACEUTICALS, INC. (Name of Subject Company) SCANDINAVIAN ACQUISITION SUB, INC. (Offeror) REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common stock,

Modification P00006 to Supply Agreement, dated as of February 24, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.6 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Firm Fixed Price Page 1 Of 6 2. Amendment/Modification No. P00006 3. Effective Date 4. Requisition/Purchase Req. No. SEE SC

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 (May 4, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorpor

Modification No. 5 to Project Agreement, dated as of March 22, 2022, by and between the Registrant and Advanced Technology International.

Exhibit 10.5 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. March 22, 2022 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY 10591 Attention: Subject: Modification No. 05 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Bas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON P

### Contact Information: Ryan Crowe Christina Chan Investor Relations Corporate Communications 914-847-8790 914-847-8827 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports First Quarter 2022 Financial and Operating Results ?First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV?(a)(b), revenues increased 25% ?First quarter 2022 EYLEA? U.S. net sales increased 13% to $1.52 billion versus first quarter 2021 ?First quarter 2022 Dupixent? global net sales(c)(recorded by Sanof

Modification No. 1 to Base Agreement, dated as of January 26, 2022, by and between the Registrant and Advanced Technology International.

Exhibit 10.4 January 26, 2022 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 Attention: Subject: Modification No. 01 Reference: MCDC Base Agreement No. 2020-504 Dear : In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 01 hereby amends the Base Agreement as follows: DESCRIPTION OF MODIFICATION 1) Article V, Section 5

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

? ?Exhibit (a)(1)(C)? Offer To Purchase For Cash All Outstanding Shares of Common Stock of CHECKMATE PHARMACEUTICALS, INC.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CHECKMATE PHARMACEUTICALS, INC.

Offer to Purchase, dated May 2, 2022.

TABLE OF CONTENTS ?Exhibit (a)(1)(A)? Offer to Purchase for Cash All Outstanding Shares of Common Stock of Checkmate Pharmaceuticals, Inc.

Summary Advertisement as published in The New York Times on May 2, 2022

Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

Confidentiality Agreement dated March 22, 2022, between Checkmate Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Exhibit (d)(2) CONFIDENTIAL Execution Version Checkmate Pharmaceuticals, Inc. 245 Main Street, 2nd Floor Cambridge, MA 02142 March 22, 2022 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Confidentiality Agreement In connection with your consideration of a possible negotiated business combination transaction involving Checkmate Pharmaceuticals, Inc. (together w

Letter of Transmittal.

? ?Exhibit (a)(1)(B)? LETTER OF TRANSMITTAL To Tender Shares of Common Stock of CHECKMATE PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CHECKMATE PHARMACEUTICALS, INC. (Name of Subject Company) SCAND

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549? ? SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934? ? CHECKMATE PHARMACEUTICALS, INC. (Name of Subject Company)? SCANDINAVIAN ACQUISITION SUB, INC. (Offeror)? REGENERON PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons)? Common stock, par

Exclusivity Agreement, dated March 22, 2022, by and between Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc.

Exhibit (d)(4) Execution Version STRICTLY CONFIDENTIAL March 22, 2022 Checkmate Pharmaceuticals, Inc.

Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

? ?Exhibit (a)(1)(D)? Offer To Purchase For Cash All Outstanding Shares of Common Stock of CHECKMATE PHARMACEUTICALS, INC.

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

DEF 14A

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Checkmate Pharmaceuticals, Inc. (Name of Subject Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Checkmate Pharmaceuticals, Inc. (Name of Subject Company) Scandinavian Acquisition Sub, Inc. (Offeror) Regeneron Pharmaceuticals, Inc. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 P

Social Media Posts from April 19, 2022 (incorporated by reference to Exhibit 99.2 to the Schedule TO-C filed by Regeneron Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on April 19, 2022).

Exhibit 99.2 [The following communication was made available by Regeneron Pharmaceuticals, Inc. on Twitter.] Forward-Looking Statements This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (?Regeneron?) and Checkmate Pharmaceuticals, Inc. (?Checkmate?) and actual events or

Joint Press Release issued by Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. on April 19, 2022 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by Regeneron Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on April 19, 2022).

Exhibit 99.1 Press Release Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types Proposed ~$250 million all-cash acquisition strengthens Regeneron?s portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical res

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 (March 2, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of (Com

BA Leasing BSC, LLC, as lessor. (Incorporated by reference from

Exhibit 10.2 Execution Version Prepared by and Upon Recording Return to: Chapman and Cutler LLP 320 S. Canal Street, 27 Floor Chicago, IL 60603 Attn: Phillip Edison Second Amended and Restated Lease and Remedies Agreement Dated as of March 2, 2022 and effective as of the Restatement Date between Old Saw Mill Holdings LLC, as Lessee and BA Leasing BSC, LLC, as Lessor Regeneron 2022 Lease Financing

Second Amended and Restated Participation Agreement, dated as of March 2, 2022, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time.

EX-10.1 2 tm222431d2ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version Second Amended and Restated Participation Agreement dated as of March 2, 2022 and effective as of the Restatement Date among Old Saw Mill Holdings LLC, as Lessee, BA Leasing BSC, LLC, as Lessor, Bank of America, N.A., not in its individual capacity, except as expressly stated herein, but solely as Administrative Agent, The

Second Amended and Restated Guaranty, dated as of March 2, 2022, made by Regeneron Pharmaceuticals, Inc., Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors.

Exhibit 10.3 Execution Version Second Amended and Restated Guaranty dated as of March 2, 2022 and effective as of the Restatement Date made by Regeneron Pharmaceuticals, Inc., as Parent Guarantor, and the Subsidiary Guarantors party hereto from time to time Table of Contents Section Heading Page Section 1. Guarantee 2 Section 2. Guarantor?s Obligations Unconditional 4 Section 3. Subordination of S

NTLA / Intellia Therapeutics Inc / Regeneron Pharmaceuticals Inc - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Intellia Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45826J105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

REGN / Regeneron Pharmaceuticals Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

ADVM / Adverum Biotechnologies Inc / Regeneron Pharmaceuticals Inc - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adverum Biotechnologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00773U108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

DBTX / Decibel Therapeutics Inc / Regeneron Pharmaceuticals Inc - SCHEDULE 13G Passive Investment

SC 13G 1 tm226027d1sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Decibel Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 24343R106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement

REGN / Regeneron Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Regeneron Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 75886F107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule

First Amendment to Amended and Restated Participation Agreement, dated as of October 6, 2021, by and among Old Saw Mill Holdings LLC, as lessee; the Registrant, as parent guarantor; certain subsidiaries of the Registrant, as subsidiary guarantors; BA Leasing BSC, LLC, as lessor; Bank of America, N.A., as administrative agent; and the lenders party thereto.

Exhibit 10.25.1 Execution Version First Amendment to Amended and Restated Participation Agreement This First Amendment to Amended and Restated Participation Agreement, dated as of October 6, 2021 (this ?Amendment?), is by and among Old Saw Mill Holdings LLC, a New York limited liability company, as Lessee (together with its successors and permitted assigns, in its capacity as Lessee, ?Lessee?); Re

Amendment No. 1 to Credit Agreement, dated as of November 11, 2021, by and among the Registrant, as a borrower and guarantor; certain direct subsidiaries of the Registrant, as subsidiary borrowers; JPMorgan Chase Bank, N.A., as administrative agent; and the lenders party thereto.

Exhibit 10.18.1 EXECUTION COPY AMENDMENT NO. 1 Dated as of November 11, 2021 to CREDIT AGREEMENT Dated as of December 14, 2018 THIS AMENDMENT NO. 1 (this ?Amendment?) is made as of November 11, 2021 by and among Regeneron Pharmaceuticals, Inc., a New York corporation (the ?Company?), Regeneron Healthcare Solutions, Inc., a New York corporation (?Solutions?), and Regeneron Genetics Center LLC, a De

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. Name of Subsidiary* State or Other Jurisdiction of Incorporation or Organization Eastside Campus Holdings LLC New York Loop Road Holdings LLC New York Old Saw Mill Holdings LLC New York OSMR Holdings Bermuda Regeneron Assurance, Inc. New York Regeneron Atlantic Holdings Bermuda Regeneron Belgium BV Belgium Regeneron Canada Company Canada

Fourth Amendment to Amended and Restated License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi.

Exhibit 10.14.4 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. FOURTH AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT THIS FOURTH AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this ?Fourth Amendment?), dated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON PHARMA

First Amendment to Immuno-oncology License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant and Sanofi Biotechnology SAS.

EX-10.20.1 4 regn-ex10201x12312021x10k.htm FIRST AMENDMENT TO IO LICENSE AND COLLAB AGREEMENT - SANOFI Exhibit 10.20.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO IMMUNO-ONCOLOGY LICENSE AND COLLABORATION AGREEMENT THIS FIRST AMENDM

### Contact Information: Mark Hudson Christina Chan Investor Relations Corporate Communications 914-847-3482 914-847-8827 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results ?Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV?(2); revenues excluding REGEN-COV(1) increased 17% ?Full year 2021 revenues increased 89% to $16.07 billion compared to full year 2020 including $6.19

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 (February 4, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

JP Morgan Healthcare Conference 2022 January 2022 This non - promotional presentation is intended for the investor audience and contains investigational data as well as forward - loo king statements; actual results may vary materially

Exhibit 99.1 JP Morgan Healthcare Conference 2022 January 2022 This non - promotional presentation is intended for the investor audience and contains investigational data as well as forward - loo king statements; actual results may vary materially This presentation includes forward - looking statements that involve risks and uncertainties relating to future events and the future performance of Reg

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 (January 10, 2022) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-

Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of U.S. Bank National Association, as trustee under the Indenture.

EX-25.1 4 tm2131319d2ex25-1.htm EXHIBIT 25.1 Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in it

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 (November 4, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENER

As filed with the Securities and Exchange Commission on November 4, 2021

S-3ASR 1 tm2131319-1s3asr.htm S-3ASR TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. 333-       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Regeneron Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) New York 13-3444607

### Contact Information: Justin Holko Christina Chan Investor Relations Corporate Communications 914-847-7786 914-847-8827 [email protected] [email protected]

EX-99.1 2 exhibit991q32021.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2021 Financial and Operating Results •Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV®(2) •Third quarter 2021 EYLEA® U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion •Third quarter 2021 Du

Modification P00004 to Supply Agreement, dated as of July 26, 2021, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Page 1 of 6 Firm Fixed Price ?? 2. Amendment/Modification No. 3. Effective Date 4. Requisition/Purchase Req No. 5. Project

Modification P00005 to Supply Agreement, dated as of September 14, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.

Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. Contract ID Code Page 1 of 12 Firm Fixed Price 2. Amendment/Modification No. 3. Effective Date 4. Requisition/Purchase Req No. 5. Project No

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 (September 14, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation)

### Contact Information: Justin Holko Hala Mirza Investor Relations Corporate Communications 914-847-7786 914-847-3422 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2021 Financial and Operating Results ?Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COVTM(2); revenues excluding REGEN-COV(1)(2) increased 22% ?Second quarter 2021 EYLEA? U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 (August 5, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON PH

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 (June 11, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034

### Contact Information: Justin Holko Hala Mirza Investor Relations Corporate Communications 914-847-7786 914-847-3422 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports First Quarter 2021 Financial and Operating Results ?First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COVTM(1) increased 20% ?First quarter 2021 EYLEA? U.S. net sales increased 15% to $1.35 billion versus first quarter 2020 ?First quarter 2021 Dupixent? global net sales(2), which are recorded

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON P

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 (May 6, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorpor

Supply Agreement, dated as of January 12, 2021, by and between

EX-10.1 2 regn-ex101x3312021x10q.htm SUPPLY AGREEMENT BY AND BETWEEN REGENERON AND US ARMY CONTRACTING COMMAND Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEM Offeror To Complete Block 12, 17, 2

-

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

-

DEFA14A 1 c101011defa14a.htm SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Soliciting Material Under Rule 14a-12 o Confidenti

-

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

DEF 14A

PROXY STATEMENT AND NOTICE OF ANNUAL SHAREHOLDER MEETING 2021PLEASE VIEW OUR 2020 ANNUAL REPORT investor.

Definitive Proxy Statement on Schedule 14A filed on April 23, 2021

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Regeneron Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 75886F107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)

Exhibit 10.3.1 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement for Time-Based Vesting Tarrytown, New York 10591 Option Awards [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted a Non-Qualified Option to buy [ ] shares of Regeneron Pharmaceuticals, Inc. (

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON PHARMA

Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to P. Roy Vagelos, M.D. under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan.

Exhibit 10.3.4 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Restricted Stock Units 777 Old Saw Mill River Road and Restricted Stock Unit Agreement Tarrytown, New York 10591 [NAME] RSU Number: [ ] [ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted restricted stock units with respect to [ ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) common sto

Agreement, dated as of October 13, 2020, by and between the Registrant and Advanced Technology International.

Exhibit 10.34.1 October 13, 2020 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY 10591 Attention: Subject: Modification No. 01 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Base Agreement No. 2020-504 Dear : In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 01 hereby amends the Project Agreement No. 01 as follows

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)

Exhibit 10.3.5 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement Tarrytown, New York 10591 [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted a Non-Qualified Option to buy [ ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) stock at $[ ] per shar

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)

Exhibit 10.3.3 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Award and Restricted Stock 777 Old Saw Mill River Road Agreement Tarrytown, New York 10591 [NAME] RSA Number: [ ] [ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted an award of [ ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) common stock. These shares are restricted until the vest da

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. Name of Subsidiary* State or Other Jurisdiction of Incorporation or Organization Loop Road Holdings LLC New York Old Saw Mill Holdings LLC New York OSMR Holdings Bermuda OSMR International Bermuda Regeneron Assurance, Inc. New York Regeneron Atlantic Holdings Bermuda Regeneron Belgium BV Belgium Regeneron Canada Company Canada Regeneron

Form of performance restricted stock unit award agreement and related notice of grant for use in connection with the grant of performance restricted stock units to Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D. under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)

Exhibit 10.3.7 REGENERON PHARMACEUTICALS, INC. ID: 13-3444607 777 Old Saw Mill River Road Tarrytown, NY 10591 Notice of Grant of Performance Restricted Stock Units and Performance Restricted Stock Unit Agreement (“Notice”) [NAME] Performance RSU Number: [ ] [ADDRESS] Plan: [ ] ID: [ ] Effective , (the “Grant Date”) you have been granted Performance Restricted Stock Units with respect to a target n

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan.

Exhibit 10.3.2 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Stock Options 777 Old Saw Mill River Road and Option Agreement for Time-Based Vesting Tarrytown, New York 10591 Option Awards [OPTIONEE NAME] Option Number: [ ] [OPTIONEE ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted a Non-Qualified Option to buy [ ] shares of Regeneron Pharmaceuticals, Inc. (

Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. (Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)

Exhibit 10.3.6 Regeneron Pharmaceuticals, Inc. ID: [ ] Notice of Grant of Restricted Stock Units 777 Old Saw Mill River Road and Restricted Stock Unit Agreement Tarrytown, New York 10591 [NAME] RSU Number: [ ] [ADDRESS] Plan: [ ] ID: [ ] Effective (the “Grant Date”) you have been granted restricted stock units with respect to [ ] shares of Regeneron Pharmaceuticals, Inc. (the “Company”) stock. The

Modification No. 02 to Project Agreement, dated as of November 17, 2020, by and between the Registrant and Advanced Technology International.

Exhibit 10.34.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. November 17, 2020 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd Tarrytown, NY 10591 Attention: Subject: Modification No. 02 to Project Agreement No. 01; MCDC2008-005 Reference: MC

(Incorporated by reference from the Form 10-K for the Registrant, for the year ended December 31, 2020, filed February 8, 2021.)

Exhibit 10.34 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. PROJECT AGREEMENT NO.: 1 MCDC BASE AGREEMENT NO.: 2020-504 PROJECT TITLE: MCDC2008-005; Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2 PARTIES: Advanced Technology International

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2021 (February 5, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

### Contact Information: Justin Holko Hala Mirza Investor Relations Corporate Communications 914-847-7786 914-847-3422 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results •Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) •Fourth quarter 2020 EYLEA® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019 •Fourth quarter 2020 Dupixent® g

Entry into a Material Definitive Agreement - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 (January 12, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 (January 11, 2021) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-

LEONARD S. SCHLEIFER MD, P h D PRESIDENT & CEO GEORGE D. YANCOPOULOS MD, P h D PRESIDENT & CSO JP MORGAN 2021 JANUARY 11 TH

Exhibit 99.1 LEONARD S. SCHLEIFER MD, P h D PRESIDENT & CEO GEORGE D. YANCOPOULOS MD, P h D PRESIDENT & CSO JP MORGAN 2021 JANUARY 11 TH 74;This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materiall

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 (December 31, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-

-

Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com December 7, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2019 Filed on February 7, 2020

Base Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended September 30, 2020, filed November 5, 2020.)

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. BASE AGREEMENT BETWEEN ADVANCED TECHNOLOGY INTERNATIONAL (ATI) 315 SIGMA DRIVE SUMMERVILLE, SC 29486 AND Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 MEDICAL C

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENER

Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International.

Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. PROJECT AGREEMENT NO.: 1 MCDC BASE AGREEMENT NO.: 2020-504 PROJECT TITLE: MCDC2008-005; Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2 PARTIES: Advanced Technology International

License Agreement, dated as of August 18, 2020, by and among the Registrant, F. Hoffman-La Roche Ltd, and Genentech, Inc. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended September 30, 2020, filed November 5, 2020.)

Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. EXECUTION VERSION License Agreement This Agreement is entered into with effect as of August 18, 2020 (the “Effective Date”) by and between F. Hoffmann-La Roche Ltd with an office and place of bu

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 (November 5, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction o

### Contact Information: Justin Holko Hala Mirza Investor Relations Corporate Communications 914-847-7786 914-847-3422 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2020 Financial and Operating Results •Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) •Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019 •Third quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 69% to $1.07 billion vers

Entry into a Material Definitive Agreement - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 (August 18, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19

Underwriting Agreement, dated August 7, 2020, by and among the Company, Goldman Sachs & Co. LLC, BofA Securities, Inc., and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 Execution Version REGENERON PHARMACEUTICALS, INC. $1,250,000,000 1.750% Senior Notes due 2030 $750,000,000 2.800% Senior Notes due 2050 UNDERWRITING AGREEMENT August 7, 2020 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 BofA Securities, Inc. One Bryant Park New York, New York 10036 J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 as Representatives of

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 (August 7, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Commission File Number 000-19034 New York 000-19034 13-3444607

First Supplemental Indenture, dated August 12, 2020, between the Registrant and U.S. Bank National Association. (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)

Exhibit 4.2 Regeneron PHARMACEUTICALS, INC., as Issuer and U.S. Bank National Association, as Trustee First Supplemental Indenture Dated as of August 12, 2020 table of contents Page ARTICLE 1 Definitions Section 1 Section 1.1. Certain Terms Defined in the Indenture 1 Section 1.2. Definitions 1 ARTICLE 2 Form and Terms of the Notes 4 Section 2.1. Form and Dating 4 Section 2.2. Terms of the Notes 6

Indenture, dated August 12, 2020, between the Registrant and U.S. Bank National Association. (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)

Exhibit 4.1 REGENERON PHARMACEUTICALS, INC., ISSUER AND U.S. Bank National Association, TRUSTEE INDENTURE DATED AS OF AUGUST 12, 2020 DEBT SECURITIES TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 SECTION 1.01 DEFINITIONS OF TERMS 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 SECTION 2.01 DESIGNATION AND TERMS OF SECURITIES 5 SECTION 2.02 FORM OF SECURITIE

Title of Each Class of Securities To Be Registered Amount To Be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) 1.750% Senior Notes due 2030 $1,250,000,000 99.898% $1,248,725

424B5 1 a2242217z424b5.htm 424B5 Use these links to rapidly review the document Prospectus Supplement TABLE OF CONTENTS Table of Contents Title of Each Class of Securities To Be Registered Amount To Be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) 1.750% Senior Notes due 2030 $1,250,000,000 99.898% $1,248,725,000 $162,08

Regeneron Pharmaceuticals, Inc. $1,250,000,000 1.750% Senior Notes Due 2030 $750,000,000 2.800% Senior Notes Due 2050 PRICING TERM SHEET $1,250,000,000 1.750% Senior Notes Due 2030

Filed Pursuant to Rule 433 Registration No. 333-228352 Free Writing Prospectus dated August 7, 2020 Relating to Preliminary Prospectus Supplement dated August 7, 2020 Regeneron Pharmaceuticals, Inc. $1,250,000,000 1.750% Senior Notes Due 2030 $750,000,000 2.800% Senior Notes Due 2050 PRICING TERM SHEET $1,250,000,000 1.750% Senior Notes Due 2030 Issuer Regeneron Pharmaceuticals, Inc. Principal Amo

Subject to Completion, dated August 7, 2020

Use these links to rapidly review the document Prospectus Supplement TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No.

Amendment No. 1 to Credit Agreement, dated as of June 11, 2020, by and between the Registrant, as borrower, and Goldman Sachs Bank USA, as administrative agent

Exhibit 10.2.1 AMENDMENT NO. 1 TO THE CREDIT AGREEMENT Dated as of June 11, 2020 AMENDMENT NO. 1 TO THE CREDIT AGREEMENT (this “Amendment”; and such Credit Agreement, as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) dated as of May 25, 2020, among REGENERON PHARMACEUTICALS, INC., a New York corporation (the “Borrower”), the Lenders party thereto,

### Contact Information: Justin Holko Hala Mirza Investor Relations Corporate Communications 914-847-7786 914-847-3422 [email protected] [email protected]

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2020 Financial and Operating Results •Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4) •Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion •Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million •Second quarter 2020 GAAP diluted EPS was $7.61 an

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 (August 5, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of in

Third Amendment to Amended and Restated License and Collaboration Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2020, filed August 5, 2020.)

Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. THIRD AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT THIS THIRD AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this “Third Amendment”), dated as of

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-19034 REGENERON PH

Praluent Cross License & Commercialization Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant and Sanofi Biotechnology SAS. (Incorporated by reference from the Form 10-Q for the Registrant, for the quarter ended June 30, 2020, filed August 5, 2020.)

Exhibit 10.4 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED. PRALUENT CROSS License & COMMERCIALIZATION AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS and REGENERON PHARMACEUTICALS, INC. Dated as of April 5, 2020 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS

Regulation FD Disclosure, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 (July 6, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034 13

REGN / Regeneron Pharmaceuticals, Inc. / Sanofi - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 (June 12, 2020) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation) 000-19034